

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CONCORD HEALTHCARE GROUP CO., LTD.**

**美中嘉和醫學技術發展集團股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2453)**

### **VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY THE CONTROLLING SHAREHOLDER OF THE COMPANY**

This announcement is made by Concord Healthcare Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to the shareholders and potential investors of the Company.

Reference is made to the announcement of the Company dated May 7, 2025 (the “**Announcement**”) in relation to the increase in shareholding by the controlling shareholder of the Company. Unless otherwise indicated, terms used in this announcement shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, Shanghai Medstar, one of the controlling shareholders (as defined under the Listing Rules) of the Company, has purchased a total of 45,600 H shares of the Company from the open market on May 7, 2025. The Board was further informed by Shanghai Medstar that it has purchased a total of 95,400 H shares of the Company from the open market for an aggregate consideration of approximately HK\$641,732.00 (representing an average price of approximately HK\$6.73 per share) from May 8, 2025 to May 9, 2025, representing approximately 0.01% of the total issued shares of the Company as at the date of this announcement. It fully demonstrates Shanghai Medstar’s confidence in the future prospects of the Company and shows support to the Company’s continuous development.

We have been granted by the Stock Exchange a waiver from strict compliance with Rule 8.08(1) (a) of the Listing Rule so as to allow a lower public float percentage of between 15% and 25% (or such higher percentage as was held by the public upon completion of the listing of the shares of the Company on the Stock Exchange). Based on the information that is publicly available to the Company and to the best knowledge of its Directors, following the completion of the increase in shareholding and as at the date of this announcement, at least 20.92% of the Company’s total number of issued shares are held by the public.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Concord Healthcare Group Co., Ltd.**  
美中嘉和醫學技術發展集團股份有限公司  
**YANG Jianyu**  
*Chairman and Executive Director*

Beijing, the PRC, May 12, 2025

*As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. CHEN Hongzhang and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.*